Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A126970-5mg | 5mg | In stock | $28.90 | |
A126970-25mg | 25mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $117.90 | |
A126970-100mg | 100mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $296.90 |
Potent, selective HSP90 inhibitor
Synonyms | Allylamino-17-demethoxygeldanamycin, 17- | CNF1010 | CNF-1010 | 17-(Allylamino) Geldanamycin | BRN 0888706 | NSC330507 | NSC-330507 | SCHEMBL309550 | CHEBI:64153 | NCGC00163424-01 | KOS 953 | Tanespimycin (17-AAG) | C76418 | UNII-4GY0AVT3L4 | 17AAG | 17-A |
---|---|
Specifications & Purity | ≥98% |
Biochemical and Physiological Mechanisms | 17-AAG is a less toxic and more stable analog of geldanamycin. It acts an Hsp90 inhibitor that displays a 100-fold higher affinity for Hsp90 derived from tumor cells compared to Hsp90 from normal cells. 17-AAG inhibits Akt1 (Akt) activation and expression |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Note | Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | 17-AAG (Tanespimycin) is a potent HSP90 inhibitor with IC50 of 5 nM, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | [(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-enylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate |
---|---|
INCHI | InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1 |
InChi Key | AYUNIORJHRXIBJ-TXHRRWQRSA-N |
Canonical SMILES | CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC |
Isomeric SMILES | C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\C=C(\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)/C)OC)OC(=O)N)\C)C)O)OC |
WGK Germany | 3 |
PubChem CID | 6505803 |
Molecular Weight | 585.69 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
C2204017 | Certificate of Analysis | Dec 21, 2023 | A126970 |
C2204034 | Certificate of Analysis | Dec 21, 2023 | A126970 |
C2204067 | Certificate of Analysis | Dec 21, 2023 | A126970 |
C1512029 | Certificate of Analysis | Nov 18, 2022 | A126970 |
Solubility | Soluble in DMSO (≥20 mg/ml at 25 °C), methanol (10 mg/ml), chloroform (10 mg/ml yielding a clear purple solution), water (<1 mg/ml at 25 °C), and ethanol (≥5 mg/ml at 25 °C). |
---|---|
Sensitivity | Light sensitive |
WGK Germany | 3 |
---|
1. Zhiyong Wang, Jinhua Wang, Songling Yang, Shuying Hou. (2016) Construction and in vitro/in vivo evaluation of 17-allylamino-17-demethoxygeldanamycin (17AAG)-loaded PEGylated nanostructured lipid carriers. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, [PMID:25853294] [10.3109/03639045.2015.1031138] |
1. Zhiyong Wang, Jinhua Wang, Songling Yang, Shuying Hou. (2016) Construction and in vitro/in vivo evaluation of 17-allylamino-17-demethoxygeldanamycin (17AAG)-loaded PEGylated nanostructured lipid carriers. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, [PMID:25853294] [10.3109/03639045.2015.1031138] |